Sensus Healthcare, Inc. (SRTS)
Market Cap | 63.37M |
Revenue (ttm) | 12.99M |
Net Income (ttm) | -6.81M |
Shares Out | 16.45M |
EPS (ttm) | -0.42 |
PE Ratio | n/a |
Forward PE | 23.15 |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 15 |
Last Price | $3.84 |
Previous Close | $3.91 |
Change ($) | -0.07 |
Change (%) | -1.79% |
Day's Open | 3.90 |
Day's Range | 3.82 - 3.94 |
Day's Volume | 5,630 |
52-Week Range | 1.83 - 4.71 |
BOCA RATON, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost...
Sensus Healthcare' (SRTS) CEO Joe Sardano on Q3 2020 Results - Earnings Call Transcript
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today
BOCA RATON, Fla, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-...
BOCA RATON, Fla. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncolo...
Sensus Healthcare' (SRTS) CEO Joe Sardano on Q2 2020 Results - Earnings Call Transcript
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today
Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems
Establishes new line of business, adds recurring revenue stream while more than doubling dermatology customer base across the state
BOCA RATON, Fla. , July 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both onc...
BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and c...
BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncolo...
BOCA RATON, Fla. , June 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncol...
BOCA RATON, Fla, June 24, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncologic...
June 18 Event is the Third in a Series of Topical Discussions
Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q1 2020 Results - Earnings Call Transcript
Retrospective registry study showed a 98.9% non-recurrence rate after 85 months in subjects with non-melanoma skin cancer treated with SRT
Sensus Healthcare's (SRTS) CEO Joe Sardano on Q4 2019 Results - Earnings Call Transcript
BOCA RATON, Fla, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cos...
New corporate structure positions company for 2020 financial goals
BOCA RATON, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and...
Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q3 2019 Results - Earnings Call Transcript
Sensus Healthcare's (SRTS) CEO Joe Sardano on Q2 2019 Results - Earnings Call Transcript
Sensus Healthcare's (SRTS) CEO Joe Sardano on Q1 2019 Results - Earnings Call Transcript
Today, we look at a small medical device maker based in South Florida.
About SRTS
Sensus Healthcare manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetr... [Read more...]
Industry Medical Devices | IPO Date Jun 3, 2016 |
CEO Joseph Sardano | Employees 53 |
Stock Exchange NASDAQ | Ticker Symbol SRTS |
Financial Performance
In 2019, SRTS's revenue was $27.26 million, an increase of 3.16% compared to the previous year's $26.43 million. Losses were -$1.70 million, -15.96% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for SRTS stock is "Buy." The 12-month stock price forecast is 4.43, which is an increase of 15.36% from the latest price.